IAP6 Rec'd PCT/PTO 26 JUN 2006

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031

Under the Page	erwork Reducti	on Act of 19	995, no perso	ns are required to rest	oond to a colle					OMB control number.
				Application Num	nber	10/575,534			_	
TRA	ANSMI	TTAL		Filing Date		April 7, 200	6			
	FORM	1		First Named Inv	entor	Gunnar Nor	rdvall			
				Art Unit		Not Known				
(to be used for al	ll corresponde	Examiner Name	•	Not Known						
. ,				Attorney Docket	t Number	101219-1P	US			
Total Number of Pages in This Submission 6 101219-17-03										
			ENC	LOSURES	(Check all t	that apply)		A 61 A 1		mmunication to TC
Amendmer Afte Afte Afte Afte Afte Afte Afte Afte	e Attached nt/Reply er Final idavits/declar of Time Requiration bandonment n Disclosure	nest Request Statemen ty g Parts	Rema	Drawing(s) Licensing-related I Petition Petition to Convert Provisional Application Power of Attorney Change of Correst Terminal Disclaim Request for Refund CD, Number of CD Landscape Tarks	t to a ation , Revocatior pondence A er ad	ddress		Appeal of Appeal (Appeal Proprie	Communica als and Inter Communica Notice, Brief, tary Informal Letter Enclosure(s)	tion to Board rferences tion to TC , Reply Brief)
uni	401 07 3 111									
		SIG	NATURE	OF APPLICAN	IT, ATTOI	RNEY, O	R AGE	NT		
Firm Name	1/		' / /)	s	<u> </u>				
Signature	Kou	, At	K	ordrad						
Printed name	Karen H. Ko	ndrad							•	
Date	6-2	2-0	6.		F	Reg. No.	38,212			
				ICATE OF TRA						
I hereby certify that sufficient postage the date shown be	as first class	pondence mail in ar	is being fac n envelope a	simile transmitted t addressed to: Comr	o the USPT	O or depos r Patents, F	sited with P.O. Box	the Uni 1450, A	ted States P Jexandria, V	ostal Service with A 22313-1450 on
Signature		Ma	rie)	Mish	eloc	1)				
Typed or printed n	name Ma	rie M. Gre		, (•			Date	Jun	F 22.2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/575,534	Applicant: Nordvall, et al.
371 Filing Date: April 7, 2006	Attorney Docket No.: 101219-1P US
Examiner: Not Known	Group Art Unit : Not Known
Customer No.: 22466	Confirmation No.: Not Known
Title: New 2-Substituted, 4-Amino-Thi	azolo[4,5-D] Pyrimidines, Useful as Chemokine
Receptor Antagonists, ESP. CX3CR1	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313;1450 on June 22, 2006

Signature
Marie M. Greloch

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

		within three	e (3) months of the filing date of a national application other	than a					
		continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months							
		of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an							
		international application, or before the mailing of the first Office Action on the							
		merits, or b	efore the mailing of a first Office Action after the filing of a I	request for					
		continued e	examination under 37 C.F.R. 1.114; or						
☐ (2	2)		eriod defined in (1) but before the mailing date of a final Actio	on or a					
			the requisite Statement is below, OR						
			the Commissioner is hereby authorized to charge the required under 37 C.F.R. 1.17(p), namely \$180.00 to deposit accomplete the required process. The commissioner is hereby authorized to charge the required process.						
□ (3)	after the ma	ailing date of a final Action or Notice of Allowance but befo	ore the					
		payment of	the Issue Fee, AND						
			the requisite Statement is below, AND						
			the Commissioner is hereby authorized to charge the req	uisite fee					
			under 37 C.F.R. 1.17(p), namely \$180.00 to deposit acco	unt No.					
			, referencing Attorney Docket No.	, or					

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 260166, referencing Attorney Docket No. 101219-1P US.

Respectfully submitted,

Name: Dated:

Karen H. Kondrad June 22, 2006

Reg. No.:

Phone No.:

38,212

302.886.8975

Global Intellectual Property, Patents,

AstraZeneca,

1800 Concord Pike,

Wilmington,

DE-19850-5437

Enclosures:

Form SB08A

Form SB08B

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Not Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/575,534 Filing Date April 7, 2006 INFORMATION DISCLOSURE First Named Inventor Gunnar Nordvall STATEMENT BY APPLICANT Art Unit

Examiner Name

(Use as many sheets as necessary)

Not Known 101219-1P US Sheet 1 Attorney Docket Number

	T-0::		U. S. PATENT D			
Examiner C Initials* No	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<u> </u>	Number-Kind Code ^{2 (# known)}			rigures Appear	
		US-				
		US-				
		US-				
		US-				
	<u> </u>	US-				
		US-				
		US-				
··· <u></u> -		US-		CONTRACTOR OF THE CONTRACTOR O		
		US-				
		US-				
		US-				
		US-		·	 	
		US-		. <u> </u>		
		US-				
		US-				
		US-	 	,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
		US-				
		US-				
		US-	1			

Examiner Cite	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	The production of the producti	Or Relevant Figures Appear	1
	A1	WO 00/09511	02-24-2000	Astra Pharmaceuticals LTD		
	A2	WO 01/58907	08-16-2001	Astrazeneca AB		
	А3	WO 01/62758 A1	08-30-2001	Astrazeneca AB		Г
	A4	WO 02/083693 A1	10-24-2002	Astrazeneca AB		Г
	A5	WO 02/076990 A1	10-03-2002	Astrazeneca AB		
	A5	WO 02/076990 A1	10-03-2002	Astrazeneca AB		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
Guostito	10 10/10/11/ 1440// 10			Application Number	10/575,534		
INFO	ORMATION	DIS	CLOSURE	Filing Date	April 7, 2006		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Gunnar Nordvall		
	(lice as many sho	ote se n	ocossani)	Art Unit	Not Known		
(Use as many sheets as necessary)				Examiner Name	Not Known		
Sheet	1	of	1	Attorney Docket Number	101219-1P US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A6	STN Internat, file CA, Chem Abstracts, Vol 60, Pfleiderer, Wolfgang, et al: "Original Ref. No. 60:5486h. "Synthesis and structure of 7-hydroxyisopterines" Abstract No. 30913	
	A7	Pfleiderer, Wolfgang, et al, "Pteridine, XXVII 1). Synthese and Struktur von 7-Hydroxy-isopterinen", Chemische Berichte, 1963, vol. 96, no. 11, page 2964-2976, Table 2, Cmpd 5	

Examiner	Date	
Signature	Considered	
9		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents P.O. Box 1450, Alexandria VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.